GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Market Cap

Aditxt (Aditxt) Market Cap : $3.25 Mil (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aditxt Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Aditxt's share price for the quarter that ended in Mar. 2024 was $3.4. Aditxt's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 1.67 Mil. Therefore, Aditxt's market cap for the quarter that ended in Mar. 2024 was $5.66 Mil.

Aditxt's quarterly market cap increased from Sep. 2023 ($4.59 Mil) to Dec. 2023 ($8.74 Mil) but then declined from Dec. 2023 ($8.74 Mil) to Mar. 2024 ($5.66 Mil).

Aditxt's annual market cap declined from Dec. 2021 ($23.81 Mil) to Dec. 2022 ($4.97 Mil) but then increased from Dec. 2022 ($4.97 Mil) to Dec. 2023 ($8.74 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Aditxt's Enterprise Value for Today is $11.34 Mil.


Aditxt Market Cap Historical Data

The historical data trend for Aditxt's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Market Cap Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
Get a 7-Day Free Trial - 27.00 23.81 4.97 8.74

Aditxt Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.40 3.04 4.59 8.74 5.66

Competitive Comparison of Aditxt's Market Cap

For the Biotechnology subindustry, Aditxt's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aditxt's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aditxt's Market Cap distribution charts can be found below:

* The bar in red indicates where Aditxt's Market Cap falls into.



Aditxt Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Aditxt's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$6.63*1.31892
=$8.74

Aditxt's Market Cap for the quarter that ended in Mar. 2024 is calculated as

Market Cap (Q: Mar. 2024 )=Share Price (Q: Mar. 2024 )*Shares Outstanding (EOP) (Q: Mar. 2024 )
=$3.4*1.66521
=$5.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aditxt  (NAS:ADTX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Aditxt Market Cap Related Terms

Thank you for viewing the detailed overview of Aditxt's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Aditxt (Aditxt) Business Description

Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
Charles Athle Nelson director 11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp 10 percent owner 787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes officer: Chief Legal Officer and GC 737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley officer: PRINCIPAL ACCOUNTING OFFICER 2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge director C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna officer: CHIEF OPERATING OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne officer: CHIEF FINANCIAL OFFICER BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony director LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna director, officer: CHIEF EXECUTIVE OFFICER 871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang director, officer: CHIEF INNOVATION OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354

Aditxt (Aditxt) Headlines

From GuruFocus

Aditxt Issues Shareholder Update

By Business Wire Business Wire 04-17-2023